NICE recommends multiple myeloma treatment

NICE has recommended the use of Revlimid (lenalidomide) for the treatment of patients with multiple myeloma, after taking into account new appraisal criteria.

The drug manufacturers, Celgene Limited, have also announced a treatment continuation scheme whereby the NHS will cover the cost of Revlimid for the first 26 cycles of treatment, which typically last one month each, with further drug costs being met by the manufacturer.

Gareth Morgan, professor of haematology at the Royal Marsden NHS Foundation Trust, said that the decision was ‘a major step toward providing a critical new option for patients in the UK’.

Eric Low, chief executive of Myeloma UK, added: ‘It is now critically important that PCTs implement this guidance immediately and I urge them to do so.’

sanjay.tanday@haymarket.com

  • Do you think PCTs will implement this guidance?

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus